{"filings":[{"id":443038,"accession_number":"0001193125-26-224101","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-05-14T20:19:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license","event_type":"earnings","confidence":"high","bullets":["Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.","Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director.","Completed $30M private placement (pre-funded and common warrants); received $7.5M milestone from Boehringer.","Exclusive license for CUE-221 (Phase 2 anti-IgE) from Ascendant Health; IND amendment for food allergy expected H2 2026.","Cash $16.4M at Mar 31, 2026; subsequent $30M private placement extends runway for clinical milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":5686000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94353,"accession_number":"0001193125-26-198588","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO","event_type":"m_and_a","confidence":"high","bullets":["License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.","Concurrent private placement raises ~$28M net via pre-funded warrants and warrants at $11.00/unit to accredited investors including new CEO.","New CEO Dr. Shao-Lee Lin appointed; participates in the private placement.","Ascendant receives pre-funded warrants for 551,724 shares at $0.001; total potential dilution from warrants exceeds 4.6M shares.","Company to seek stockholder approval for share issuances under Nasdaq rules; special meeting within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94352,"accession_number":"0001193125-26-168907","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Cue Biopharma files 1-for-30 reverse stock split to maintain Nasdaq listing","event_type":"other_material","confidence":"high","bullets":["1-for-30 reverse stock split effective 5:00 PM ET on April 23, 2026; no fractional shares, cash in lieu.","Common stock begins trading post-split on April 24 under symbol CUE; new CUSIP 22978P205.","Reverse split aims to meet Nasdaq minimum bid price requirement, as disclosed in proxy statement.","No change in authorized shares ($0.001 par); options and warrants proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94351,"accession_number":"0001193125-26-152826","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cue Biopharma stockholders approve reverse stock split with ratio 1:30 to 1:50","event_type":"other_material","confidence":"high","bullets":["Elected Pasha Sarraf, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, and Jill Broadfoot to the Board.","Ratified RSM US LLP as independent auditor for FY2026 with 58,982,168 votes for.","Approved non-binding advisory say-on-pay with 31,388,709 for, 4,239,819 against.","Approved reverse stock split amendment at 51,011,729 for; ratio range 1-for-30 to 1-for-50 at Board's discretion.","Prior CEO Usman Azam resigned March 26, 2026; votes for him were disregarded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94350,"accession_number":"0001193125-26-144569","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cue Biopharma achieves preclinical milestone with Boehringer Ingelheim; $7.5M payment due May 2026","event_type":"other_material","confidence":"high","bullets":["Boehringer Ingelheim approved selection of first compound for lead optimization under April 2025 collaboration.","Milestone triggers $7.5M payment to Cue Biopharma, expected in May 2026.","Collaboration targets differentiated B cell depletion molecules including CUE-501."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106636,"accession_number":"0001193125-26-128993","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma CEO Usman Azam resigns; Lucinda Warren named Interim CEO","event_type":"leadership","confidence":"high","bullets":["Usman Azam resigned as President, CEO and Board member effective March 26, 2026.","Lucinda Warren, previously CFO and CBO, appointed Interim President and CEO effective March 27, 2026; retains CFO and CBO roles.","Warren's base salary $525,000; eligible for 45% target bonus and up to 1.0% stock option upon financing milestone.","Azam severance: lump sum $232,500 (3 months salary plus 25% of 2026 target bonus) plus up to 12 months COBRA.","Warren receives $10,000/month supplemental until new CEO hired or 12-month anniversary, with lump sum if earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106635,"accession_number":"0001193125-26-108292","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M","event_type":"earnings","confidence":"high","bullets":["Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.","Collaboration revenue $21.9M in Q4 vs $1.6M; primarily from $9.5M upfront from ImmunoScape deal, with $5M due Nov 2026.","R&D expenses $16.5M (up from $7.2M) on CUE-401 mfg and ImmunoScape-related costs; G&A $3.5M (down from $4.0M).","Appointed Lucinda Warren CFO; raised $10.2M net in public offering; cash $27.1M at Dec 31, 2025.","Advanced CUE-401 autoimmune drug toward IND; reported preclinical safety data; plans Virtual R&D Day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106634,"accession_number":"0001193125-26-056983","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cue Biopharma sets 2026 annual meeting for April 13; shareholder deadlines on Feb 28.","event_type":"other_material","confidence":"high","bullets":["Annual meeting date: April 13, 2026.","Shareholder proposals under Rule 14a-8 must be received by February 28, 2026.","Director nominations and other business also due by February 28, 2026 per Bylaws and Rule 14a-19.","Proxies may exercise discretionary voting on late proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106633,"accession_number":"0001193125-26-047717","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma appoints CBO Lucinda Warren as CFO effective Feb 9, 2026","event_type":"leadership","confidence":"high","bullets":["Lucinda Warren, previously CBO, named Chief Financial & Business Officer; assumes principal financial/accounting officer duties.","Warren had been CBO since Sept 2024; prior VP Business Development at Johnson & Johnson (2014-2024).","No additional compensation or changes to her employment agreement for the CFO role.","No family relationships with directors/officers; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122964,"accession_number":"0001193125-25-326925","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.","Net proceeds ~$8.9M (~$10.3M if underwriters exercise full option), after underwriting discounts and expenses.","Cash runway extended into Q1 2027 based on net proceeds, existing cash, and expected $10M from ImmunoScape collaboration.","Underwriters have 30-day option to purchase up to 5,357,140 additional shares and 2,678,570 warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122963,"accession_number":"0001193125-25-292093","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cue Biopharma posts updated corporate presentation on website; no specific new facts disclosed","event_type":"other","confidence":"low","bullets":["Company made an updated corporate presentation available on its website on November 24, 2025.","The presentation was furnished as Exhibit 99.1 to the 8-K filing.","No financial results, material transactions, or forward-looking guidance were included in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122962,"accession_number":"0001193125-25-289713","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma CMO Matteo Levisetti to depart Nov 28; gets $556,838 severance","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Matteo Levisetti will terminate employment effective November 28, 2025.","Severance includes lump sum of $556,837.60 (nine months base salary plus prorated 2025 bonus).","COBRA premiums paid by company for up to nine months post-separation if elected.","Payment conditioned on execution and nonrevocation of a separation and release agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122961,"accession_number":"0001193125-25-277468","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q3 net loss $0.07/sh; ImmunoScape deal $15M upfront; new CEO","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $7.45M ($0.07 EPS); revenue $2.15M (down 36% YoY); cash $11.7M (down 48% from Dec 2024).","Collaboration with ImmunoScape: upfront total $15M ($10M in Q4 2025, $5M in Nov 2026) plus 40% equity stake.","Usman Azam appointed President & CEO effective Sep 29; leadership transition to advance autoimmune asset CUE-401.","CUE-101+pembrolizumab in HPV+ HNSCC: 50% ORR, 88% 12-month OS, median OS 32.7 months.","R&D spend $4.8M (down 49% YoY); G&A $4.9M (up 72% YoY) due to severance and professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":5524000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122960,"accession_number":"0001193125-25-268135","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity","event_type":"m_and_a","confidence":"high","bullets":["Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.","Cue Biopharma receives $15M upfront ($10M in Q4 2025, $5M in Nov 2026) and 40% equity stake in ImmunoScape.","Cue Biopharma eligible for high-single-digit royalties on net sales of any products developed.","IND-enabling studies on track for 2027 submission; preclinical data shown in pancreatic and ovarian cancer models.","Cue Biopharma to focus on autoimmune disease programs while oncology development advances with ImmunoScape."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139667,"accession_number":"0000950130-25-000140","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma appoints Usman Azam as CEO, succeeding Daniel Passeri who transitions to advisor","event_type":"leadership","confidence":"high","bullets":["Usman Azam appointed President and CEO effective Sept 29, 2025; succeeds Daniel Passeri who retires and becomes strategic advisor.","Azam receives base salary $620,000, bonus target 50% of base, stock options for 2.25M shares (1.875M time-based + 375K performance-based).","Passeri receives lump sum severance of $838,750, 12-month equity vesting acceleration, and COBRA for 18 months.","Passeri advisor agreement: stock option for 375K shares tied to financing milestone, term through March 30, 2026, with continued equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139666,"accession_number":"0000950170-25-107268","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones","event_type":"earnings","confidence":"high","bullets":["Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.","Announced collaboration with Boehringer Ingelheim for CUE-501: $12M upfront, up to $345M milestones.","Received FDA Pre-IND feedback supporting CUE-401 IND for autoimmune disease.","CUE-101 Phase 1 data: 50% ORR, 88% 12-mo OS, median OS 32 months in HPV+ HNSCC.","Raised ~$20M via public offering; cash position $27.5M at June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":3374000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139665,"accession_number":"0000950170-25-092168","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cue Biopharma reduces monthly rent 37% and extends Boston lease to April 2028","event_type":"other_material","confidence":"high","bullets":["Monthly rent cut from $235,884 to $147,546, effective June 30, 2025.","Lease term extended by two years to April 14, 2028, from prior April 14, 2026.","Landlord granted a partial rent credit of $44,169 for June 2025.","Rent subject to a 4% increase on April 15, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157247,"accession_number":"0000950170-25-084279","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Cue Biopharma CFO resigns, elects Jill Broadfoot to board, increases authorized shares to 310M","event_type":"leadership","confidence":"high","bullets":["CFO Kerri-Ann Millar resigns effective June 13, 2025; CEO Daniel Passeri will be interim principal financial and accounting officer.","Jill Broadfoot appointed to board and Audit Committee chair; granted option to purchase 48,800 shares.","Authorized shares of capital stock increased from 210M to 310M; common stock from 200M to 300M.","Stockholders approved 2025 Stock Incentive Plan (13.85M for, 2.01M against); also elected all director nominees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}